Sponsored by
An abstract shared recently at the ASCO conference suggests that a new protocol involving the addition of metformin may improve outcomes for patients with newly diagnosed GBM. In this Phase 2 trial in Canada, 50 patients received metformin alongside temozolomide (TMZ) prior to surgery, during an accelerated radiation regimen (60 Gy in 4 weeks), and during 6 cycles of maintenance chemo, and were compared to 50 matched patients who received the standard Stupp protocol. The group treated with the investigational protocol had a significantly longer median survival time - 24.1 months compared to 17.7 months in the standard care group - as well as improved progression-free survival (13.7 months vs 11.0 months). Notably, patients with methylated MGMT tumors who also had a gross total resection saw even more dramatic benefits, with median survival reaching 41.9 months versus 17.8 months in matched controls.